Novartis
NEWS
There has been a string of news stories about how big pharma is teaming up with various artificial intelligence (AI) companies to leverage real-world data and speed drug development.
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.
One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.
For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.
Swiss pharma giant Novartis supported the company’s Series C financing round with a $75 million equity investment.
Just as Novartis and AveXis’ gene therapy, Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) is progressing toward approval, a second patient death was reported.
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
JOBS
IN THE PRESS